Boehringer Ingelheim has secured FDA approval for Jascayd (nerandomilast) tablets to treat progressive pulmonary fibrosis (PPF) in adults, the therapy’s second U.S. indication following idiopathic pulmonary fibrosis. The decision rests on the phase III FIBRONEER-ILD program, which demonstrated statistically significant preservation of forced vital capacity over 52 weeks versus placebo, with discontinuation rates comparable to placebo. Jascayd is the first selective PDE4B inhibitor approved in PPF and enters a market previously anchored by antifibrotic therapy.
The strategic significance is twofold. First, Boehringer extends its respiratory leadership from IPF into the broader PPF phenotype with a differentiated mechanism that straddles immunomodulation and antifibrosis. Second, the label emerges as combination-ready in a real-world setting where clinicians often layer therapies in a heterogeneous, multispecialty population. The trial permitted background antifibrotic use, and while gastrointestinal events were more frequent when Jascayd was combined with nintedanib, overall tolerability and discontinuation remained manageable. That creates a practical—if nuanced—path for add-on adoption, but also raises the commercial question of whether payers will sanction routine dual therapy without clear, controlled evidence of additive outcomes beyond lung function.
For patients and clinicians, the approval broadens options in a disease where diagnosis is delayed and progression is unpredictable across autoimmune ILDs, hypersensitivity pneumonitis, and unclassifiable forms. The primary FVC result aligns with regulators’ growing comfort with lung function preservation as a surrogate in chronic fibrosing ILDs. Yet the key secondary composite of exacerbations, respiratory hospitalizations, or death did not reach statistical significance, with signals emerging only in exploratory cuts. That evidentiary nuance matters for access: payers may demand post-approval data to confirm reductions in acute events and healthcare utilization, particularly if prescribing patterns shift toward combination use. The burden of proof will likely move to real-world evidence, time-to-treatment-failure metrics, and subgroup outcomes that reflect the diversity of PPF etiologies managed across pulmonology and rheumatology.
Commercially, Boehringer is now both incumbent and challenger. Nintedanib holds the only existing PPF approval among antifibrotics; Jascayd introduces a mechanism that could be positioned as first-line monotherapy in select phenotypes or as an add-on in patients with ongoing decline. The company’s hub infrastructure and payer engagement will need to navigate step edits, prior authorization criteria tied to FVC trends, and potential guardrails on concurrent therapy. Pricing will be scrutinized against claims of complementary benefit, tolerability in the community setting, and the magnitude of functional preservation relative to historical antifibrotic benchmarks.
The approval also reinforces broader industry currents. Phenotype-based labels in fibrosis are gaining traction as sponsors pivot from single-disease silos to cross-etiology programs. Selective PDE4 targeting could re-energize small-molecule approaches in fibroinflammation after setbacks in autotaxin and anti-CTGF pathways, especially if longer-term data validate exacerbation and survival trends. For Medical Affairs, this is a catalyst to harmonize diagnostic pathways, educate non-pulmonary specialists who encounter underlying autoimmune drivers, and build prospective registries that capture treatment sequences, add-on effects, and patient-reported outcomes.
The next competitive frontier is evidence of combination value. If Boehringer can generate convincing RWE that pairing Jascayd with antifibrotics translates FVC gains into fewer exacerbations and hospitalizations without unacceptable GI burden, payer skepticism could soften and a new standard could form. The open question for 2026: will PPF management pivot from sequential monotherapy to deliberate, phenotype-driven combination therapy—and who will bring the proof that changes practice and budgets?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
